Search

Sanofi SA

Chiusa

SettoreSettore sanitario

84.57 -0.21

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

84.09

Massimo

84.94

Metriche Chiave

By Trading Economics

Entrata

1.1B

2.9B

Vendite

129M

11B

P/E

Media del settore

16.656

37.257

EPS

1.59

Rendimento da dividendi

4.52

Margine di Profitto

27.303

Dipendenti

82,878

EBITDA

-881M

1.9B

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+24.85% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

4.52%

2.94%

Utili prossimi

24 ott 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

463M

105B

Apertura precedente

84.78

Chiusura precedente

84.57

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Sanofi SA Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 ott 2025, 08:42 UTC

I principali Market Mover

U.K. Bank Shares Rise After Regulator Softens Car-Loan Redress Estimate

3 ott 2025, 10:40 UTC

Acquisizioni, Fusioni, Takeovers

Santander UK CEO Stands Down Ahead of TSB Integration

1 ott 2025, 08:54 UTC

I principali Market Mover

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

4 set 2025, 08:58 UTC

I principali Market Mover

Sanofi Shares Sink as Experimental Drug Results Disappoint

4 ago 2025, 10:06 UTC

I principali Market Mover

U.K. Bank Shares Rise After Car-Loan Ruling Softens Industry Blow -- Update

31 lug 2025, 06:00 UTC

Utili

Sanofi Upbeat on Sales Outlook After Faster-Than-Expected Growth

6 ott 2025, 08:15 UTC

Discorsi di Mercato

Sanofi's Profitability Stronger Than It Looks -- Market Talk

3 ott 2025, 14:10 UTC

Discorsi di Mercato

Sanofi Sales Could Miss Forecasts, With Adjusted Profit in Line -- Market Talk

3 ott 2025, 10:06 UTC

Acquisizioni, Fusioni, Takeovers

Santander's Regnier Says He Is Leaving to Allow Successor to Lead TSB Integration

3 ott 2025, 10:03 UTC

Acquisizioni, Fusioni, Takeovers

Santander: Appointment Process to Find Successor Has Started

3 ott 2025, 10:02 UTC

Acquisizioni, Fusioni, Takeovers

Santander: Mike Regnier to Step Down by 1Q 2026

3 ott 2025, 10:01 UTC

Acquisizioni, Fusioni, Takeovers

Santander UK CEO to Step Down

1 ott 2025, 07:53 UTC

Discorsi di Mercato

Pfizer's U.S. Pricing Move Brings Clarity for Pharma Sector -- Market Talk

5 set 2025, 08:24 UTC

Discorsi di Mercato

Sanofi's Eczema Drug Candidate Could Still Become a Blockbuster -- Market Talk

5 set 2025, 06:55 UTC

Discorsi di Mercato

Sanofi Share Fall After Eczema Trial Results Looks Overdone -- Market Talk

28 ago 2025, 09:00 UTC

Discorsi di Mercato

Santander Could Deliver Even Higher Returns -- Market Talk

6 ago 2025, 05:02 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi Completes the Acquisition of Vigil Neuroscience

6 ago 2025, 05:00 UTC

Acquisizioni, Fusioni, Takeovers

Press Release: Sanofi Completes The Acquisition Of Vigil Neuroscience, Inc. >SAN.FR

1 ago 2025, 13:16 UTC

Utili

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 ago 2025, 12:40 UTC

Utili

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

31 lug 2025, 08:15 UTC

Discorsi di Mercato
Utili

Sanofi's Higher Costs Take Shine off Outlook Raise -- Market Talk

31 lug 2025, 05:56 UTC

Discorsi di Mercato
Utili

Sanofi in the Dark on Pharma Tariffs After U.S.-EU Deal -- Market Talk

31 lug 2025, 05:30 UTC

Utili

Sanofi 2Q Vaccine Sales Increased 10% to EUR1.2B

31 lug 2025, 05:30 UTC

Utili

Sanofi Says Pharma Launches Sales Increased by 40% in 2Q

31 lug 2025, 05:30 UTC

Utili

Sanofi 2Q Dupixent Sales Grew 21% to EUR3.8B

31 lug 2025, 05:30 UTC

Utili

Sanofi Intends to Complete EUR5B Buyback in 2025, With 80% Repurchased to Date

31 lug 2025, 05:30 UTC

Utili

Sanofi: 2025 Business EPS Guidance Now Includes Expenses From Acquisitions

31 lug 2025, 05:30 UTC

Utili

Sanofi 2Q Business Operating Profit EUR2.46B

31 lug 2025, 05:30 UTC

Utili

Sanofi 2Q Adj EPS EUR1.59

31 lug 2025, 05:30 UTC

Utili

Analysts Saw Sanofi 2Q Business Operating Profit at EUR2.57B

Sanofi SA Previsione

Obiettivo di Prezzo

By TipRanks

24.85% in crescita

Previsioni per 12 mesi

Media 105.92 EUR  24.85%

Alto 121.052 EUR

Basso 92.806 EUR

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sanofi SA - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

14 ratings

12

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

91.3 / 96.1Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

Bullish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
help-icon Live chat